FI3720428T3 - Dobesiliinihappoa käsittävä oftalminen paikalliskoostumus silmän takasegmentin sairauksien hoitoon - Google Patents
Dobesiliinihappoa käsittävä oftalminen paikalliskoostumus silmän takasegmentin sairauksien hoitoon Download PDFInfo
- Publication number
- FI3720428T3 FI3720428T3 FIEP18811023.3T FI18811023T FI3720428T3 FI 3720428 T3 FI3720428 T3 FI 3720428T3 FI 18811023 T FI18811023 T FI 18811023T FI 3720428 T3 FI3720428 T3 FI 3720428T3
- Authority
- FI
- Finland
- Prior art keywords
- acid
- salt
- pharmaceutically acceptable
- acceptable salt
- ester
- Prior art date
Links
- IKQCSJBQLWJEPU-UHFFFAOYSA-N 2,5-dihydroxybenzenesulfonic acid Chemical compound OC1=CC=C(O)C(S(O)(=O)=O)=C1 IKQCSJBQLWJEPU-UHFFFAOYSA-N 0.000 title claims 19
- 229940049636 dobesilic acid Drugs 0.000 title claims 19
- 201000010099 disease Diseases 0.000 title claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 7
- 230000000699 topical effect Effects 0.000 title claims 5
- 150000003839 salts Chemical class 0.000 claims 39
- 239000002253 acid Substances 0.000 claims 22
- 150000002148 esters Chemical class 0.000 claims 15
- 208000002780 macular degeneration Diseases 0.000 claims 10
- -1 alkali metal salt Chemical class 0.000 claims 8
- 230000007170 pathology Effects 0.000 claims 8
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 5
- 208000035719 Maculopathy Diseases 0.000 claims 4
- 210000001328 optic nerve Anatomy 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 206010003694 Atrophy Diseases 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 3
- 206010063381 Polypoidal choroidal vasculopathy Diseases 0.000 claims 3
- 208000017442 Retinal disease Diseases 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 229910052783 alkali metal Inorganic materials 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- 230000037444 atrophy Effects 0.000 claims 3
- 208000033379 Chorioretinopathy Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000001351 Epiretinal Membrane Diseases 0.000 claims 2
- 208000031471 Macular fibrosis Diseases 0.000 claims 2
- 208000009702 Optic Disk Drusen Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 208000027073 Stargardt disease Diseases 0.000 claims 2
- 208000014769 Usher Syndromes Diseases 0.000 claims 2
- 208000034699 Vitreous floaters Diseases 0.000 claims 2
- 229960005438 calcium dobesilate Drugs 0.000 claims 2
- QGNBTYAQAPLTMX-UHFFFAOYSA-L calcium dobesilate Chemical group [Ca+2].OC1=CC=C(O)C(S([O-])(=O)=O)=C1.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 QGNBTYAQAPLTMX-UHFFFAOYSA-L 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- 239000000790 retinal pigment Substances 0.000 claims 2
- 208000000318 vitreous detachment Diseases 0.000 claims 2
- 208000003569 Central serous chorioretinopathy Diseases 0.000 claims 1
- 208000033825 Chorioretinal atrophy Diseases 0.000 claims 1
- 208000008515 Choroidal sclerosis Diseases 0.000 claims 1
- 208000003492 Fundus albipunctatus Diseases 0.000 claims 1
- 208000033463 Ischaemic neuropathy Diseases 0.000 claims 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims 1
- 206010059239 Leukaemic retinopathy Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 206010025421 Macule Diseases 0.000 claims 1
- 208000009857 Microaneurysm Diseases 0.000 claims 1
- 208000024080 Myopic macular degeneration Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010061323 Optic neuropathy Diseases 0.000 claims 1
- 206010033733 Papule Diseases 0.000 claims 1
- 208000036891 RDH5-related retinopathy Diseases 0.000 claims 1
- 208000036903 RLBP1-related retinopathy Diseases 0.000 claims 1
- 206010064714 Radiation retinopathy Diseases 0.000 claims 1
- 208000021016 Retinal Arterial Macroaneurysm Diseases 0.000 claims 1
- 208000002367 Retinal Perforations Diseases 0.000 claims 1
- 206010064145 Retinal aneurysm Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 208000014633 Retinitis punctata albescens Diseases 0.000 claims 1
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims 1
- 208000032458 Retinopathy solar Diseases 0.000 claims 1
- 208000027077 Stickler syndrome Diseases 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 208000036866 Vitreoretinopathy Diseases 0.000 claims 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 claims 1
- 208000022482 Wagner disease Diseases 0.000 claims 1
- 208000029977 White Dot Syndromes Diseases 0.000 claims 1
- 208000023564 acute macular neuroretinopathy Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 210000003161 choroid Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 208000014188 hereditary optic neuropathy Diseases 0.000 claims 1
- 201000001948 hypertensive retinopathy Diseases 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 208000029233 macular holes Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 201000002165 neuroretinitis Diseases 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 208000020911 optic nerve disease Diseases 0.000 claims 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 208000032253 retinal ischemia Diseases 0.000 claims 1
- 201000001184 retinal microaneurysm Diseases 0.000 claims 1
- 230000004286 retinal pathology Effects 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 210000003786 sclera Anatomy 0.000 claims 1
- 201000000824 solar retinopathy Diseases 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 239000008009 topical excipient Substances 0.000 claims 1
- 208000029517 toxic amblyopia Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382832 | 2017-12-04 | ||
| PCT/EP2018/082999 WO2019110416A1 (en) | 2017-12-04 | 2018-11-29 | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3720428T3 true FI3720428T3 (fi) | 2023-03-30 |
Family
ID=60673756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18811023.3T FI3720428T3 (fi) | 2017-12-04 | 2018-11-29 | Dobesiliinihappoa käsittävä oftalminen paikalliskoostumus silmän takasegmentin sairauksien hoitoon |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20200390729A1 (https=) |
| EP (1) | EP3720428B1 (https=) |
| JP (1) | JP7846501B2 (https=) |
| KR (1) | KR102756155B1 (https=) |
| CN (1) | CN111542316A (https=) |
| AU (1) | AU2018378981B2 (https=) |
| BR (1) | BR112020011160A2 (https=) |
| CA (1) | CA3083835A1 (https=) |
| CL (1) | CL2020001426A1 (https=) |
| DK (1) | DK3720428T3 (https=) |
| ES (1) | ES2941036T3 (https=) |
| FI (1) | FI3720428T3 (https=) |
| HR (1) | HRP20230319T1 (https=) |
| HU (1) | HUE061852T2 (https=) |
| MA (1) | MA50991B1 (https=) |
| MX (1) | MX2020005809A (https=) |
| MY (1) | MY205498A (https=) |
| PH (1) | PH12020550722A1 (https=) |
| PL (1) | PL3720428T3 (https=) |
| PT (1) | PT3720428T (https=) |
| SG (1) | SG11202004940VA (https=) |
| SI (1) | SI3720428T1 (https=) |
| WO (1) | WO2019110416A1 (https=) |
| ZA (1) | ZA202003944B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202300017430A1 (it) * | 2023-08-22 | 2025-02-22 | Service Biotech srl | Soluzione oftalmica in forma di collirio contenente una isoforma umana ricombinante di manganese superossido dismutasi (rmnsod) per la cura di patologie dell’occhio |
| CN117257963B (zh) * | 2023-11-02 | 2024-07-16 | 广州准优生物科技有限公司 | 含脐带间充质干细胞外泌体的眼用药剂及其制备方法和用途 |
| CN117643573B (zh) * | 2024-01-29 | 2024-05-03 | 天津医科大学眼科医院 | 一种可递送药物至眼后节的纳米滴眼液及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE51421B1 (en) * | 1980-08-01 | 1986-12-24 | Smith & Nephew Ass | Ophthalmic compositions containing triamterene |
| US9198886B2 (en) * | 2006-08-16 | 2015-12-01 | Pedro Cuevas Sánchez | Use of 2,5-dihydroxybenzene for the treatment of ocular diseases |
| JP2015500213A (ja) | 2011-11-30 | 2015-01-05 | ザイジェン インフラメーション リミテッド | 眼乾燥症候群を処置するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用 |
| EP2777699B1 (en) | 2012-02-02 | 2017-03-29 | Invesfovea S.L. | Diethylamine-2,5-dihydroxybenzenesulfonate for the treatment of age-related macular degeneration |
| CA2866405A1 (en) | 2012-03-05 | 2013-09-12 | Wayne State University | Identification of channelopsin-2 (chop2) mutations and methods of use |
| RU2014140116A (ru) | 2012-04-24 | 2016-06-10 | Тромбодженикс Н.В. | Антитела против pdgf-c |
| EP2875811A1 (en) | 2013-11-26 | 2015-05-27 | Luis Antonio Outeirino Miguez | Use of dobesilate for treating ocular haemorrhages |
-
2018
- 2018-11-29 DK DK18811023.3T patent/DK3720428T3/da active
- 2018-11-29 EP EP18811023.3A patent/EP3720428B1/en active Active
- 2018-11-29 MA MA50991A patent/MA50991B1/fr unknown
- 2018-11-29 HR HRP20230319TT patent/HRP20230319T1/hr unknown
- 2018-11-29 MY MYPI2020002628A patent/MY205498A/en unknown
- 2018-11-29 ES ES18811023T patent/ES2941036T3/es active Active
- 2018-11-29 FI FIEP18811023.3T patent/FI3720428T3/fi active
- 2018-11-29 PT PT188110233T patent/PT3720428T/pt unknown
- 2018-11-29 PL PL18811023.3T patent/PL3720428T3/pl unknown
- 2018-11-29 SG SG11202004940VA patent/SG11202004940VA/en unknown
- 2018-11-29 CN CN201880082202.1A patent/CN111542316A/zh active Pending
- 2018-11-29 KR KR1020207018983A patent/KR102756155B1/ko active Active
- 2018-11-29 US US16/770,027 patent/US20200390729A1/en active Pending
- 2018-11-29 HU HUE18811023A patent/HUE061852T2/hu unknown
- 2018-11-29 JP JP2020529733A patent/JP7846501B2/ja active Active
- 2018-11-29 WO PCT/EP2018/082999 patent/WO2019110416A1/en not_active Ceased
- 2018-11-29 AU AU2018378981A patent/AU2018378981B2/en active Active
- 2018-11-29 CA CA3083835A patent/CA3083835A1/en active Pending
- 2018-11-29 BR BR112020011160-0A patent/BR112020011160A2/pt unknown
- 2018-11-29 SI SI201830869T patent/SI3720428T1/sl unknown
- 2018-11-29 MX MX2020005809A patent/MX2020005809A/es unknown
-
2020
- 2020-05-27 PH PH12020550722A patent/PH12020550722A1/en unknown
- 2020-05-28 CL CL2020001426A patent/CL2020001426A1/es unknown
- 2020-06-29 ZA ZA2020/03944A patent/ZA202003944B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI3720428T1 (sl) | 2023-05-31 |
| CA3083835A1 (en) | 2019-06-13 |
| ES2941036T3 (es) | 2023-05-16 |
| EP3720428A1 (en) | 2020-10-14 |
| WO2019110416A1 (en) | 2019-06-13 |
| KR102756155B1 (ko) | 2025-01-20 |
| KR20200096569A (ko) | 2020-08-12 |
| ZA202003944B (en) | 2022-12-21 |
| PH12020550722A1 (en) | 2021-02-15 |
| CN111542316A (zh) | 2020-08-14 |
| JP7846501B2 (ja) | 2026-04-15 |
| HRP20230319T1 (hr) | 2023-05-12 |
| CL2020001426A1 (es) | 2020-11-06 |
| AU2018378981A1 (en) | 2020-07-16 |
| EP3720428B1 (en) | 2023-01-11 |
| BR112020011160A2 (pt) | 2020-11-17 |
| MX2020005809A (es) | 2020-08-20 |
| HUE061852T2 (hu) | 2023-08-28 |
| DK3720428T3 (da) | 2023-03-20 |
| US20200390729A1 (en) | 2020-12-17 |
| JP2021505554A (ja) | 2021-02-18 |
| MA50991B1 (fr) | 2023-03-31 |
| MA50991A (fr) | 2020-10-14 |
| PT3720428T (pt) | 2023-04-03 |
| PL3720428T3 (pl) | 2023-05-08 |
| MY205498A (en) | 2024-10-23 |
| SG11202004940VA (en) | 2020-06-29 |
| AU2018378981B2 (en) | 2024-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011284589B2 (en) | Compounds for the treatment/prevention of ocular inflammatory diseases | |
| JP2008538215A5 (https=) | ||
| JP2014533274A5 (https=) | ||
| WO2008111497A1 (ja) | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 | |
| RU2761436C1 (ru) | Композиции и способы лечения нарушений со стороны органа зрения | |
| RU2009145939A (ru) | Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза | |
| JP2022548071A5 (https=) | ||
| RU2018128980A (ru) | Офтальмологические составы для доставки лекарственных средств к заднему сегменту глаза | |
| IL290069B1 (en) | Methods for treating eye conditions | |
| FI3720428T3 (fi) | Dobesiliinihappoa käsittävä oftalminen paikalliskoostumus silmän takasegmentin sairauksien hoitoon | |
| RU2014123472A (ru) | Производные 4-прегенен-11ss-17-21-триол-3,20-диона для лечения глазных болезней | |
| CN109549918A (zh) | 一种眼用药物组合物、眼用药盒及其医药应用 | |
| JP2021503449A5 (https=) | ||
| AU2023201678A1 (en) | Methods for the use of 5'-adenosine diphosphate ribose (ADPR) | |
| JP6116714B2 (ja) | 眼科炎症疾患治療用点眼剤組成物及びその製造方法 | |
| JPWO2020145364A5 (https=) | ||
| CN111315369A (zh) | 用于治疗眼部病症和皮肤疾病的化合物、组合物和方法 | |
| RU2018102746A (ru) | Офтальмологическая фармацевтическая композиция | |
| JP2021505554A5 (https=) | ||
| US20240033246A1 (en) | Compounds for treating eye diseases and disorders | |
| ES2624446T3 (es) | Compuestos donantes de óxido nítrico a base de quinona para uso oftalmológico | |
| RU2019118904A (ru) | Распределение в глазу и фармакокинетика композиций лифитеграста | |
| JP2012505928A5 (https=) | ||
| TW201705956A (zh) | 唑系抗真菌藥之對眼瞼皮膚的投與 | |
| HURWITZ et al. | Uses of naphazoline (privine®) in ophthalmology |